首页> 外文OA文献 >Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

【2h】

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

机译：每两周一次i.v.的疗效和安全性晚期或转移性乳腺癌，卵巢癌，结肠直肠癌，胰腺癌，小细胞癌和非小细胞肺癌的患者的独立队列研究中使用Aurora激酶抑制剂盐酸丹那替比治疗：一项多肿瘤，多机构的II期研究

页面导航

摘要
著录项
相似文献
相关主题

摘要

This multi-centre phase II trial assessed the activity, safety (CTCAE 3.0) and pharmacokinetics (PK) of the pan-Aurora kinase inhibitor danusertib hydrochloride (PHA-739358) in breast (BC), ovarian (OC), pancreatic (PC), colorectal (CRC), small-cell (SCLC) and non-small-cell lung (NSCLC) cancers.

机译：这项多中心的II期临床试验评估了Pan-Aurora激酶抑制剂盐酸danusertib盐酸盐（PHA-739358）在乳腺癌（BC），卵巢（OC），胰腺（PC）中的活性，安全性（CTCAE 3.0）和药代动力学（PK），结直肠癌（CRC），小细胞癌（SCLC）和非小细胞肺癌（NSCLC）。

著录项

作者
Schöffski Patrick; Besse B; Gauler T; de Jonge M J A; Scambia G; Santoro A; Davite C; Jannuzzo M G; Petroccione A; Delord J-P;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献

1. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study [J] . Schoffski P., Besse B., Gauler T., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第3期

机译：每两周一次i.v.的疗效和安全性晚期或转移性乳腺癌，卵巢癌，结肠直肠癌，胰腺癌，小细胞癌和非小细胞肺癌的患者的独立队列研究中使用Aurora激酶抑制剂盐酸丹那替比治疗：一项多肿瘤，多机构的II期研究
2. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study [J] . Melichar Bohuslav, Adenis Antoine, Lockhart A. Craig, The lancet oncology . 2015,第4期

机译：研究性极光激酶A抑制剂alisertib在乳腺癌，小细胞肺癌，非小细胞肺癌，头颈部鳞状细胞癌和胃食管腺癌患者中的安全性和活性：五分手臂2期研究
3. 53LBA A phase I/IIa study of icotinib hydrochloride (BPI-2009H), an oral epidermal growth factor receptor tyrosine kinases inhibitor, in patients with advanced non-small-cell lung cancer and other solid tumors [J] . Q.Zhao, J.Zhou, J.Shentu, European Journal of Cancer Supplements . 2009,第3期

机译：53LBA A阶段的I / IIa研究盐酸可替尼（BPI-2009H），一种口服表皮生长因子受体酪氨酸激酶抑制剂，用于晚期非小细胞肺癌和其他实体瘤患者
4. A randomized multicenter phase II study comparing efficacy safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer [O] . Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, 2021

机译：随机的多中心期II研究比较晚期或转移性非小细胞肺癌患者的二铂肽和Pemetrexed两种剂量方案的疗效安全性和耐受性进行比较
5. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer [O] . Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, 2021

机译：随机的多中心期II研究比较晚期或转移性非小细胞肺癌患者的二铂肽和Pemetrexed两种剂量方案的疗效，安全性和耐受性进行比较

摘要

著录项

相似文献

相关主题

期刊订阅